17 septembre 2006
Bryntsalov Makes Ready Ferein for Sale
Presidential candidate of 1996 and pharmaceutical mogul Vladimir Bryntsalov has launched the pre-sale preparation of Ferein, the fifth pharmaceutical enterprise of Russia, the Business newspaper reported.
The root cause of Ferein’s sale is the recent checks of the tax bodies, Business says, by results of which the company’s managers were accused of producing the fake medicine, including of famous brands of the West.
AFK Sistema is tipped as the most probable buyer of Ferein. Sistema declined to comment officially, but a source with it confirmed the talks with Vladimir Bryntsalov were underway.
Sistema that has bought out some pharmaceutical and medical assets this year intends to set up a pharmaceutical holding capable of developing, producing and selling both the original medicaments and generics.
The recent difficulties of Ferein are by far not the first clashes of the company with authorities. In 2001, for instance, the Health Ministry recalled its license for the haw tincture. Alcohol made up 70 percent of tincture’s content, Deputy Health Minister Anton Katlinsky said then.
16 juin 2006
le marché pharmaceutique russe
Unhealthy Growth
Russia’s pharmaceutical market stepped up 30 percent in January to April, DSM Group reported yesterday. The market grew 35 percent past year, which is the absolute record for Russia and the highest world indicator reported in 2005. The stunning results could be mostly attributed to introduction of additional beneficial provision of medicine in Russia, but it will hardly drive the market in future. Regardless, DSM Group estimates the market will be annually gaining 18 percent on average from 2006 to 2010, and its size will go up from $9 billion to $17.2 billion.
The world market of medicine grew just 7 percent in 2005 vs. 13 percent in 2001, IMS health reported, blaming the lack in speed on the slow pace of the U.S. and European markets. In this environment, the market of Russia will be more and more attractive for foreign firms, PwC analysts forecast.
According to PwC, development of pharmaceutical market in Russia is fueled by improving welfare of the nation and its impairing health.
“In Russia, the share of cardiovascular and cancer diseases is gradually increasing. Moreover, unlike developed countries, the cancer is being revealed very late,” said Academician Sergey Kolesnikov from Russian Medical Science Academy.
When it comes to cancer, Russia is in line with developed countries – 17 percent to 22 percent of death cases overall. The situation is even worse with cardiovascular diseases, where Russia is long well ahead of developed world – 56 percent of all death cases in 2004. Of 1,000 people, seven die of cardiovascular diseases in Russia, World Health Organization (WHO) reported, pointing out it is the absolute record.
But effective treatment of cancer and cardiovascular diseases requires more efficient and expensive medicine. The demand for such medicaments, which is usually met by the drugs of foreign make, goes up along with the growth in diseases.
by www.kommersant.com
